Can Donor Milk Revolutionize Formula Feeding? A New Study Seeks Answers

GILBERT, Ariz. – July 20, 2026 – For decades, the infant feeding landscape has been framed as a binary choice: breast milk or formula. But a new partnership between a disruptive food-tech company and a precision science lab aims to prove the power of a third option, potentially reshaping nutrition for millions of infants.

Leche, a company that pioneered shelf-stable, consumer-driven donor breast milk, has joined forces with Tiny Health, an at-home microbiome testing specialist. Together, they have announced a clinical study to investigate a simple but profound question: can adding a small, daily amount of donor breast milk to a formula-fed baby’s diet significantly improve their gut health? This collaboration marks a pivotal moment, moving the conversation beyond a polarizing debate and toward a scientifically validated 'middle ground'.

"For years the conversation has been breast versus formula, as if those are the only two options a family gets," said Trish Clifford, co-founder of Leche. "Most parents end up somewhere in between, and until now nobody has actually studied what that middle ground does for a baby's health." This study, she implies, is about giving that option the science to back it up.

Redefining the 'Middle Ground' in Infant Nutrition

The science is clear: breast milk is the gold standard for infant nutrition. The World Health Organization and the American Academy of Pediatrics recommend exclusive breastfeeding for the first six months of life, citing a wealth of benefits linked to immune function, cognitive development, and reduced risk of chronic disease. Much of this advantage stems from the development of the infant gut microbiome.

Human milk contains a complex cocktail of about 150 to 200 unique sugars known as human milk oligosaccharides (HMOs). These HMOs act as prebiotics, selectively feeding beneficial bacteria like Bifidobacterium that come to dominate the gut of a healthy breastfed baby. This specific microbial profile is crucial for training the immune system and protecting against pathogens.

Infant formula, while a safe and nutritionally complete alternative, has historically lacked this biological complexity. While leading brands have begun adding one or two synthetically produced HMOs to their products, they cannot replicate the full, diverse spectrum found in human milk. This study seeks to determine if supplementing with real donor milk—which retains its full range of HMOs even after Leche's freeze-drying and pasteurization process—can help a formula-fed baby’s gut develop a more 'breastfed-like' pattern.

This research is particularly relevant given that two-thirds of American babies receive formula at some point in their first year. By focusing on this large demographic, the study addresses a practical reality for countless families who, for reasons ranging from medical issues to work demands, cannot or choose not to exclusively breastfeed.

The Science Behind the Study: A Look Under the Hood

To measure the impact of this 'middle ground' approach, the partners are deploying cutting-edge scientific tools. The study will follow a straightforward before-and-after design, enrolling 100 healthy, full-term, formula-fed infants.

At the outset, Tiny Health will analyze each baby’s gut microbiome using an at-home test kit. For the next month, families will add a modest daily amount of Leche’s powdered donor breast milk to their baby's existing formula feeds. At the end of the month-long intervention, Tiny Health will conduct a second, independent test to measure any changes.

The analytical engine behind this is shotgun metagenomics, a powerful sequencing technology that provides a comprehensive snapshot of the gut ecosystem. Unlike older methods that only identify bacteria, this technique can determine the specific species present and, crucially, their functional capabilities—what the bacteria are genetically equipped to do.

"This is one of the first studies to examine whether adding a small, consistent amount of donor breast milk to an otherwise formula-fed infant’s diet can produce measurable shifts in microbiome composition and function,” said Cheryl Sew Hoy, Founder and CEO of Tiny Health. The researchers will be looking for specific markers: a significant increase in beneficial Bifidobacterium levels, evidence that the gut is becoming better equipped to metabolize HMOs, and an overall shift toward the microbial patterns seen in breastfed infants.

While the study's one-month duration and 100-participant size are typical for an initial, exploratory trial, its findings could have major implications. Positive results would provide the first rigorous, microbiome-based evidence for supplementing formula with donor milk, potentially paving the way for larger studies on long-term health outcomes.

The Business of Breast Milk: Innovation Meets a Niche Market

The study also highlights a significant business innovation. Leche is not a traditional milk bank. The Human Milk Banking Association of North America (HMBANA) oversees a network of non-profit banks that primarily serve medically fragile, premature infants in neonatal intensive care units. Their donor milk is a precious, prescription-based resource.

Leche, founded by mothers Jenney Korasick and Trish Clifford, has taken a different path. By developing an innovative freeze-drying process, the company created a shelf-stable product that can be sold directly to consumers. This 'consumer-driven' model aims to make the benefits of donor milk accessible to the much larger market of healthy, full-term infants—a market largely unserved by the traditional system.

This approach places Leche at the intersection of food tech and consumer packaged goods, a space fraught with both opportunity and challenges. The company must navigate a complex regulatory landscape, as the FDA has different standards for food, infant formula, and human tissue. It must also build consumer trust in the safety of its sourcing and processing, and address the ethical considerations inherent in commercializing a human product.

A successful outcome in the Tiny Health study would be a powerful marketing and validation tool, providing the scientific credibility needed to justify its premium product and differentiate it from both standard formula and informal milk-sharing networks. It would represent a strategic masterstroke, using hard science to legitimize a new category in the multi-billion-dollar infant nutrition industry.

With enrollment for the study set to open on August 1, the results, expected later this year, will be closely watched by pediatricians, investors, and parents alike. The findings could provide a new, evidence-based tool for infant health, validating a 'middle ground' that reflects the realities of modern parenthood and demonstrating how technology and business can converge to redefine one of life's most fundamental needs.